Moderna’s 2022 Shot Orders Edge Up Amid Easing Pandemic (1)

Orders for Moderna Inc.’s Covid-19 vaccine rose only modestly in the last six weeks as it battles rivals for market share amid fading pandemic concerns, although the company is still waiting to see whether the U.S. places new booster orders for later this year.

The messenger RNA vaccine maker said it has signed $19 billion worth of agreements for 2022 sales of its shot, up from $18.5 billion announced in January. But the company also said in an quarterly earnings statement that options for 2022 orders were $3 billion, down from $3.5 billion announced earlier.

Still, Chief Executive Officer ...